Clonality in stem cell derived therapies, a journey from process development to manufacturing
With a 30% growth rate and a projected $14 billion market by 2025, cell therapy, the use of cells as the actual therapy, is one of the most promising and increasingly valuable sectors in science. Emergent companies in this space have an eye on the future production of clinical treatments. Whatever the timescale, the question of when and how to implement practices that will be scalable to cGMP (current Good Manufacturing Practice) often arise.
In this document, Solentim describes why it is important to adopt a GMP 'mind set' early on in the process and how Solentim products support the development of stem cell therapies. Moreover, read a commentary from Simon Hoffman, cGMP Consultant, on Good Manufacturing Practice standards.
Please complete the form below and we’ll instantly send you an email with a link to the White Paper:
Please double-check your ‘junk’ folder for the email from our [email protected] address.